Nurix Therapeutics, Inc. - 8-K Filing
Nurix Therapeutics entered a $700 million upfront payment collaboration with Roche for bexobrutideg, its BTK degrader. The deal includes up to $2.3 billion in potential milestone payments and shared U.S. profits/losses (50% each), plus royalties on ex-U.S. sales. Development costs will be split 40% by Nurix and 60% by Roche. (Items: 1.01 Entry into a Material Definitive Agreement, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $NRIX